
Andreas Geier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7001730/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. Journal of Hepatology, 2018, 69, 896-904.	3.7	1,157
2	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
3	Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 283-308.	4.1	275
4	Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver. Journal of Immunology, 2016, 196, 97-105.	0.8	210
5	Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology, 2013, 57, 1394-1406.	7.3	197
6	Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology, 2003, 38, 345-354.	7.3	195
7	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut, 2022, 71, 1006-1019.	12.1	195
8	Mechanisms of Disease: mechanisms and clinical implications of cholestasis in sepsis. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 574-585.	1.7	193
9	Fecal SCFAs and SCFAâ€producing bacteria in gut microbiome of human NAFLD as a putative link to systemic Tâ€cell activation and advanced disease. United European Gastroenterology Journal, 2018, 6, 1496-1507.	3.8	190
10	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2020, 18, 728-735.e4.	4.4	167
11	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. Journal of Lipid Research, 2017, 58, 247-255.	4.2	159
12	Non-Alcoholic Fatty Liver Disease. Deutsches Ärzteblatt International, 2014, 111, 447-52.	0.9	134
13	Animal models of NAFLD from a hepatologist's point of view. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 943-953.	3.8	132
14	Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS ONE, 2015, 10, e0142661.	2.5	116
15	Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Liver International, 2015, 35, 1133-1144.	3.9	104
16	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	12.1	100
17	Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. American Journal of Physiology - Renal Physiology, 2005, 289, C831-C841.	3.4	94
18	Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1609, 87-94.	2.6	76

ANDREAS GEIER

#	Article	IF	CITATIONS
19	Adaptation of iron transport and metabolism to acute high-altitude hypoxia in mountaineers. Hepatology, 2013, 58, 2153-2162.	7.3	71
20	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	1.8	71
21	Liver Phenotypes of European Adults Heterozygous or Homozygous for Piâ^—Z Variant of AAT (Piâ^—MZ vs) Tj E	TQq1,1 0. 1.3	784314 rgBT 63
22	Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: effect of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World Journal of Gastroenterology, 2003, 9, 2681.	3.3	62
23	Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. Journal of Hepatology, 2005, 43, 1021-1030.	3.7	56
24	Non-invasive assessment of NAFLD as systemic disease—A machine learning perspective. PLoS ONE, 2019, 14, e0214436.	2.5	56
25	Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine and Growth Factor Reviews, 2015, 26, 625-635.	7.2	55
26	A common polymorphism in the <i>ABCB11</i> gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clinical Science, 2011, 120, 287-296.	4.3	44
27	From the origin of NASH to the future of metabolic fatty liver disease. Gut, 2021, 70, 1570-1579.	12.1	43
28	Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterology, 2018, 53, 1114-1120.	1.5	41
29	Cytokine-independent repression of rodentNtcp in obstructive cholestasis. Hepatology, 2005, 41, 470-477.	7.3	40
30	Epigenetic events involved in organic cation transporter 1â€dependent impaired response of hepatocellular carcinoma to sorafenib. British Journal of Pharmacology, 2019, 176, 787-800.	5.4	39
31	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. Journal of Lipid Research, 2019, 60, 1270-1283.	4.2	37
32	Hepatocyte nuclear factor-4α is a central transactivator of the mouse Ntcp gene. American Journal of Physiology - Renal Physiology, 2008, 295, G226-G233.	3.4	34
33	Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. World Journal of Gastroenterology, 2016, 22, 72.	3.3	34
34	Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis. Nutrients, 2019, 11, 77.	4.1	33
35	Shedding new light on vitamin D and fatty liver disease. Journal of Hepatology, 2011, 55, 273-275.	3.7	32
36	Intestinal vitamin D receptor modulates lipid metabolism, adipose tissue inflammation and liver steatosis in obese mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1567-1578.	3.8	30

ANDREAS GEIER

#	Article	IF	CITATIONS
37	Hepatitis B virus: The "metabolovirus―highjacks cholesterol and bile acid metabolism. Hepatology, 2014, 60, 1458-1460.	7.3	29
38	Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans. American Journal of Physiology - Renal Physiology, 2014, 307, G673-G688.	3.4	29
39	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. Journal of Human Genetics, 2018, 63, 621-626.	2.3	29
40	The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. Frontiers in Medicine, 2019, 6, 61.	2.6	26
41	Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies. Digestive Diseases, 2016, 34, 356-363.	1.9	25
42	Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 625-640.	3.3	23
43	Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. Biological Chemistry, 2010, 391, 1441-9.	2.5	22
44	Nonâ€alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?. JDDG - Journal of the German Society of Dermatology, 2021, 19, 517-528.	0.8	22
45	Regulation of organic anion transporters in a new rat model of acute and chronic cholangitis resembling human primary sclerosing cholangitis. Journal of Hepatology, 2002, 36, 718-724.	3.7	21
46	Fasting induces basolateral uptake transporters of the SLC family in the liver via HNF4α and PGC1α. American Journal of Physiology - Renal Physiology, 2007, 293, G585-G590.	3.4	21
47	Effect of drug transporter pharmacogenetics on cholestasis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1533-1551.	3.3	21
48	Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. Inflammatory Bowel Diseases, 2016, 22, 2382-2389.	1.9	21
49	Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. Scandinavian Journal of Gastroenterology, 2016, 51, 1263-1268.	1.5	21
50	Real-World Burden of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1020-1029.e7.	4.4	21
51	An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy. Expert Review of Clinical Pharmacology, 2021, 14, 333-340.	3.1	20
52	SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR. Journal of Hepatology, 2019, 70, e796-e797.	3.7	19
53	Occult celiac disease prevents penetrance of hemochromatosis. World Journal of Gastroenterology, 2005, 11, 3323.	3.3	19
54	Bile acids are "homeotrophic―sensors of the functional hepatic capacity and regulate adaptive growth during liver regeneration. Hepatology, 2007, 45, 251-253.	7.3	18

ANDREAS GEIER

#	Article	IF	CITATIONS
55	Screening for nonalcoholic fatty liver disease-when, who and how?. World Journal of Gastroenterology, 2021, 27, 5803-5821.	3.3	18
56	Emerging therapies for NASH - the future is now. Expert Review of Clinical Pharmacology, 2017, 10, 467-469.	3.1	15
57	Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force or innocent bystanders?. Hepatology, 2018, 67, 464-466.	7.3	15
58	Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferonâ€Î± and ribavirin in chronic hepatitis C virus patients. Liver International, 2014, 34, 551-557.	3.9	13
59	Magnetic resonance imaging and magnetic resonance cholangiopancreaticography for diagnosis and pre-interventional evaluation of a fluid thoracic mass. European Journal of Gastroenterology and Hepatology, 2003, 15, 429-431.	1.6	12
60	Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report. Rheumatology, 2017, 56, 1628-1629.	1.9	11
61	Farnesoid X receptor-dependent and -independent pathways mediate the transcriptional control of human fibroblast growth factor 19 by vitamin A. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 381-392.	1.9	10
62	Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. PLoS ONE, 2016, 11, e0158512.	2.5	9
63	A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients – single-center real-world experience of outpatient clinical practice. Zeitschrift Fur Gastroenterologie, 2019, 57, 1209-1217.	0.5	8
64	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. Hepatology, 2017, 66, 666-667.	7.3	7
65	Non-invasive diagnosis of patients with â€~at-risk' NAFLD : only fibrosis counts?. Gut, 2020, 69, 1164-1165.	12.1	7
66	Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. Journal of Clinical Medicine, 2022, 11, 753.	2.4	4
67	Profuse rectal bleeding of no visible cause. Lancet, The, 2007, 369, 1664.	13.7	3
68	Ulcerating Ileocolitis in Severe Amatoxin Poisoning. Case Reports in Gastrointestinal Medicine, 2015, 2015, 1-4.	0.3	3
69	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. PLoS ONE, 2018, 13, e0208225.	2.5	3
70	The ¹³ Câ€methactin breath test is nonâ€inferior to liver biopsy in predicting liverâ€related death and transplantation: A 7â€year prospective followâ€up study in 132 patients with chronic hepatitis C infection. GastroHep, 2020, 2, 344-350.	0.6	2
71	Liver Disease, Nonalcoholic Fatty. , 2020, , 408-413.		1
72	Defense Barriers in the Body:Contribution of Multidrug Resistance-Associated Protein 2. Comments on Modern Biology Part B, Comments on Toxicology, 2003, 9, 201-214.	0.2	0

#	Article	IF	CITATIONS
73	Transcriptional control of cells by vitamin D and its role in liver health and disease. , 2020, , 651-671.		0
74	Effect of high altitude on human postprandial 13 Câ€octanoate metabolism, intermediary metabolites, gastrointestinal peptides, and visceral perception. Neurogastroenterology and Motility, 2021, , e14225.	3.0	0